PROMISE

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

What will happen during the trial?

The goal of the PROMISE research study is to determine clinical/genomic alterations present in individuals with MGUS and SMM, who are diagnosed though screening of a high-risk population. We also seek to determine clinical/genomic/epigenetic and immune environmental predictors of progression to multiple myeloma in patients with MGUS and SMM.

More Information

Trial Status
Accepting patients
Trial Phase
Observational Trial
Enrollment
30,000 patients (estimated)
Sponsors
Dana-Farber Cancer Institute
Collaborators
Stand Up To Cancer
Tags
High Risk, Observational, Participate From Home
Trial Type
Observational
Last Update
1 month ago
SparkCures ID
979
NCT Identifier
NCT03689595

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.